Adamas Pharmaceuticals’ (ADMS) “Hold” Rating Reaffirmed at Needham & Company LLC

Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “hold” rating reissued by stock analysts at Needham & Company LLC in a research note issued on Friday, AnalystRatings.com reports.

A number of other research firms have also recently commented on ADMS. Evercore ISI reaffirmed a “buy” rating and issued a $55.00 target price on shares of Adamas Pharmaceuticals in a research report on Monday, August 12th. Cowen set a $5.00 target price on shares of Adamas Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, August 9th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. Bank of America cut shares of Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $9.00 to $5.00 in a research report on Monday, September 30th. Finally, Cantor Fitzgerald initiated coverage on shares of Adamas Pharmaceuticals in a research report on Monday, September 9th. They set a “neutral” rating and a $8.00 price target on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $17.13.

NASDAQ ADMS traded up $0.29 during trading hours on Friday, reaching $4.99. The company had a trading volume of 33,330 shares, compared to its average volume of 398,056. The stock has a 50-day moving average of $4.74 and a 200 day moving average of $5.53. Adamas Pharmaceuticals has a 1-year low of $3.35 and a 1-year high of $13.29. The company has a current ratio of 7.27, a quick ratio of 7.05 and a debt-to-equity ratio of 3.05. The stock has a market capitalization of $119.97 million, a P/E ratio of -1.01 and a beta of 1.61.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 149.97%. The company had revenue of $13.93 million during the quarter, compared to analyst estimates of $14.36 million. As a group, sell-side analysts predict that Adamas Pharmaceuticals will post -3.74 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Adamas Pharmaceuticals by 10.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 46,928 shares of the specialty pharmaceutical company’s stock worth $291,000 after buying an additional 4,381 shares during the period. Fisher Asset Management LLC increased its stake in Adamas Pharmaceuticals by 19.6% in the second quarter. Fisher Asset Management LLC now owns 138,724 shares of the specialty pharmaceutical company’s stock valued at $860,000 after purchasing an additional 22,705 shares during the last quarter. Advisor Group Inc. increased its stake in Adamas Pharmaceuticals by 53.4% in the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 3,900 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in Adamas Pharmaceuticals by 63.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Worth Venture Partners LLC increased its stake in Adamas Pharmaceuticals by 47.2% in the second quarter. Worth Venture Partners LLC now owns 87,908 shares of the specialty pharmaceutical company’s stock valued at $545,000 after purchasing an additional 28,168 shares during the last quarter. Hedge funds and other institutional investors own 63.22% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

See Also: Quiet Period Expirations Explained

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply